16:38 EDT 4D Molecular (FDMT) sees cash, equivalents funding planned operations into 2028
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular announces RMAT designation granted by FDA for 4D-150 for DME
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- 4D Molecular price target lowered to $40 from $42 at BofA
- 4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue